StockTipsArenaBeta

BUY Dr. Lal Path Labs Ltd. — Sudeep Shah, SBICAP Securities

BUYDr. Lal Path Labs Ltd.
Dr. Lal Path Labs share price target & all analyst calls

bySudeep Shah, SBICAP SecuritiesHorizon: NA (inferred Swing (≤2wk))9 Nov 2026via Zee Business (Live)

Entry₹2,049.5Inferred
Target₹2,150
Total upside +4.90%
Stop loss₹1,970-3.88% risk
CMP₹1,9931d ago
Active-2.76%+7.88%upside left 8d left
Follow Sudeep Shah for new calls(43% target hit, 81 closed calls)Get alertsWatch LALPATHLAB for new buy/sell callsGet alertsSee 281 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:41 am IST
8 supporting0 opposing
Supports the BUY call (8)

MACD above its signal line — bullish momentum

Technicals · macd·14 Nov · today

Dr. Lal PathLabs reported Q2 FY27 consolidated revenue of Rs 874 Cr, up 19.6% YoY, with PAT of Rs 194 Cr, up 27.5% YoY. The company also declared an interim dividend of Rs 5 per share.

NSE · Press Release·4 Nov · 1w ago

(opens in new tab)

Dr. Lal PathLabs reported Q2 FY27 consolidated revenue of Rs 874 Cr, up 19.6% YoY, with PAT increasing 27.5% to Rs 194 Cr. The company also declared an interim dividend of Rs 5 per share.

BSE · Company Update·4 Nov · 1w ago

(opens in new tab)

The company reported financial results for the quarter and half-year ended September 30, 2026, declared a second interim dividend of INR 5 per share, and announced a further investment of INR 49.5 cro

BSE · Company Update·4 Nov · 1w ago

(opens in new tab)

The company reported financial results for the quarter and half year ended September 30, 2026, and declared a second interim dividend of INR 5 per equity share.

NSE · Outcome of Board Meeting·4 Nov · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Lal Path Labs

All analyst calls on Dr. Lal Path Labs

More from Sudeep Shah, SBICAP Securities

Every call and its outcome